References
- Mahmoudian M, Rahimi-Moghaddam P. The anti-cancer activity of Noscapine: a review. Recent Pat Anticancer Drug Discov 2009;4:92–97
- Martindale WA. The extra pharmacopoeia. London: The Pharmaceutical Press; 1997
- Aneja A, Dhiman N, Idnani J, et al. Preclinical pharmacokinetics and bioavailability of Noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007;60:831–839
- Landen JW, Lang R, McMohan SJ, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Clin Cancer Res 2002;62:4109–4114
- Landen JW, Hau V, Wang M, et al. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004;10:5187–5201
- Madan J, Dhiman N, Parmar VK, et al. Inclusion complexes of Noscapine in β-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemother Pharmacol 2010;65:537–548
- Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201–230
- Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 2007;123:78–99
- Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005;2:335–351
- Ungell AL, Nylander S, Bergstrand S, et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998;87:360–366
- Higuchi T, Connors AK. Phase solubility techniques. Adv Anal Chem Instrum 1965;4:117–212
- Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol 2006;2:715–731